Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems. Ingram Publishing/Getty Images The global market for highly potent active pharmaceutical ...

Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...

As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and ...

This article discusses a number of factors that may influence the behaviour of conjugated biopharmaceuticals. Optimizing bioconjugation processes may be critical to achieve the desired drug ...

Antibody-drug conjugates (ADCs) are formed by covalent biochemical conjugation of monoclonal antibodies (mAb) with payload drugs through small molecular linkers. They are regarded as an emerging class ...

The use of antibodies as delivery vehicles for drug payloads in antibody–drug conjugates (ADCs) and simplified variants of traditional antibody models (i.e., nanobodies) are particularly versatile ...

NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three ...